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Introduction
The alarming rise in the incidence of obesity worldwide has emerged 
as one of the most pressing public health issu es in recent years [1]. 
The obesity pandemic is thought to be associated with a sedentary 
lifestyle and the overconsumption of energy-rich food. It is clear that 
obesity raises the incidence of some co-morbid health risks such 
as diabetes, hypertension, cardiovascular and metabolic diseases 
[2]. Despite the enormity of the obesity pandemic and the wealth 
of information that has been gained in the past decade about the 
hormonal  and transcriptional mechanisms that regulate energy 
metabolism, there are only two drugs currently approved by the FDA 
for the treatment of obesity.These include orlistat that blocks the 
absorption of dietary fat [3], and sibutramine, a specific reuptake 
inhibitor for norepinephrine and serotonin that acts in the central 
nervous system (CNS) to reduce energy intake [4]. These drugs have 
limited efficacies and side effects are commonly reported [5], which 
are further confounded by diminishing response in the long-term 
treatment of obesity [6,7]. The loss of efficacy, which may be a result 
of drug induced tolerance, not only occurs with the first generation 
appetite suppressant but are observed with the other classes of 
drug candidates as well including  rimonabant [8],  leptin [9],  and 
melanotan  II [10].    Moreover,  anti-obesity  drug development 
strategy continues to focus on either central or peripheral acting 
inhibitors of food intake [11], which will likely encounter similar 
problems [6]. Recent suspension of sibutramine in Europe, and the 
FDA-issued warning of heart risk in patients taking sibutramine 
further limit the pharmacotherapeutic option for obesity.
The completion of some recent late stage anti-obesity clinical 
trials using combinations of various repositioned drugs including 
anticonvulsant, antidepressant and a controlled substance of 
the amphetamine class, seemed to meet FDA criteria for clinical 
efficacy [12]. Other than the novel monotherapeutic lorcaserin, 
these repositioned drugs, however, all have a history of safety 
issues.  The potential side effects associated with the long-term use 
of these agents remain to be evaluated.   Despite these progresses, 
it is imperative to identify new drugs to address the unmet needs 
for the treatment of obesity. 
Some compounds in plants have been developed for their use 
in insect pest management without harming the environment 
[13]. Prieurianin, a limonoid isolated from several plant species, 
exhibits specific anti-feedant activity in insect using a diet choice 
bioassay [14].   The drug has no apparent effects on the efficiency 
of conversion of ingested food in larvae and seems to antagonize 
20-hydroxyecdysone activity in Drosophila cells [14, 15]. 
In light of its ability to deter feeding in insects, we hypothesized 
that prieurianin would interfere with feeding behaviour in mice 
and cause weight loss.   In this report, we showed that prieurianin 
suppresses appetite and causes weight loss in diet-induced obese 
mice and inhibits adipogenesis in cell culture model of preadipocytes. 
Our results suggest that prieurianin may be an effective anti-obesity 
drug candidate and also serve as a pharmacological tool for probing 
the biology of adipose tissue.  
Materials and Methods 
Animals, diets, drugs, and reagents 
 All animal procedures were approved by the Institutional 
Animal Care and Use Committee. For all in vivo efficacy studies, 
prieurianin was dissolved in DMSO and then given intraperitoneally 
as a mixture in 10% Cremophor EL (Sigma-Aldrich, St. Louis, MO) [16] 
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Abstract
The global increase in the incidence of obesity has emerged as one of the most serious public health risks in 
recent years. Despite the enormity of the obesity pandemic, there are currently only two FDA-approved therapies for 
its treatment and these drugs exhibit modest effi cacy and have limiting side effects. Prieurianin is a plant limonoid 
product that deters feeding in insect larvae. We investigated in this study the effects of prieurianin on weight loss and 
adipogenesis. Our results showed that prieurianin causes weight loss by reducing energy intake in obese mice on high-
calorie diet. We also found that prieurianin is anti-adipogenic in cultured preadipocytes and adipocytes by inhibiting 
proliferation and differentiation of preadipocytes into adipocytes, and induces either dedifferentiation or delipidation 
of mature adipocytes. Whether prieurianin can potentially be used for obesity treatment in human warrants further 
investigation.
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to the animals, and vehicle-treated controls received equivolume 
injections of 0.5% of DMSO in Cremophor. For diet-induced obesity 
studies, 12-14 week-old normal C57BL/6 (B6) mice (The Jackson 
Laboratory, Bar Harbor, ME) were acclimatized for at least one week 
on a 12-hour light/dark cycle at 68-72oF and then fed a high-fat 
diet containing 45 kcal% fat (Research Diets, Inc., New Brunswick, 
NJ), until their mean body weight reached approximately 30 g, and 
remained on the high-fat diet for the duration of the study. Mice had 
access to the high fat diet ad libitum during treatment in all studies. 
Blood glucose and insulin levels were measured and adipose tissues 
were harvested for weighing at the end of the experiments. Food 
intake and body weight were measured every two days for the 
duration of the study. Mice were euthanized by CO2 asphyxiation 
according to the Association for Assessment and Accreditation of 
Laboratory Animal Care International guidelines. All studies were 
performed with at least 10 to 20 animals per group. 
Prieurianin was obtained from MicroSource Discovery Systems 
(Gaylordsville, CT), and sibutramine from Sigma-Aldrich (St. Louis, 
MO). Tumor necrosis factor  was cloned into the pGEX-6P-1 vector 
(GE Healthcare, Piscataway, NJ) as a fusion protein with glutathione 
Stransferase and produced from E. coli following IPTG induction and 
purification as described according to manufacturer’s specification. 
Cell culture and adipocyte differentiation
NIH-3T3/L1 (L1) (American Type Culture Collection, 
Manassas, VA) and OP9 stromal (a gift of Dr. Perry Bickel, 
University of Texas Health Science Center, Houston, TX) 
cells were cultured at 37°C with 10% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% (v/v) fetal calf serum (Invitrogen), 1 
mM sodium pyruvate, 0.1 mM non-essential amino acids, 2 
mM L-glutamine, 100 g ml-1 streptomycin sulfate, and 100 
U ml-1 penicillin. To assess preadipocytes proliferation, cells 
were plated in 12 well dishes and then treated with various 
concentrations of prieurianin. Cell growth was measured daily on 
a Coulter cell counter. To differentiate L1 cells into adipocytes, 
cells were incubated with 250 nM dexamethasone, 450 M 
3-isobutyl-1-methylxanthine, and 167 nM insulin for 2 days, followed 
by 167 nM insulin for an additional 3 days as described (17). For OP9 
cells (18), differentiation was initiated with a serum replacement 
medium composed of MEM-a with 15% KnockOut SR (Invitrogen,), 
100 g ml1 streptomycin sulfate, and 100 U ml-1 penicillin, for 2 
days and then replenished in the propagation medium as above.
Nile Red (Sigma, St. Louis, MO) staining following differentiation 
was performed as described by adding a 1 mg ml-1 stock solution 
to cultured cells to a final concentration of 5 g ml-1 and then 
visualized under fluorescence microscope [19], and compared to 
preadipocytes differentiated in the presence of prieurianin. To 
determine the effect of prieurianin on dedifferentiation/lipolysis, 
preadipocytes were differentiated into adipocytes as above and 
further cultured for 5-6 days, and then treated with or without drug 
for an additional 5-6 days before Nile Red staining. 
Annexin V assay
The Guava Nexin assay measures membrane changes associated 
with apoptosis using Annexin V-PE, and 7-aminoactinomycin D 
(7-AAD) to identify dead cells, and experiments were conducted 
according to manufacturer’s specification (Millipore, Billerica, MA). 
In brief, preadipocytes in culture were treated with prieurianin 
for 24 hours and then resuspended in 1X Nexin buffer solution, 
supplemented with 5 l of Annexin-V solution and 5 l of 7-AAD. 
To ensure the binding of the label, samples were incubated on ice. 
Finally, the 1X Nexin buffer was added and samples were analyzed 
in the Guava cytometer. 
Glucose, insulin and adipose tissues
Fed glucose and insulin levels were measured from blood 
samples taken at the end of the treatment period. Glucose was 
measured using Cardio Chek meter (PTS, Indianapolis, IN). Insulin 
levels were measured in plasma using an ELISA kit (Crystal Chem 
Inc., Downers Grove, IL). Necropsy analysis was performed for two 
fat depots, subcutaneous and visceral fat, by weighing the dissected 
tissues. 
Statistical analyses
Statistical analyses were performed using commercially 
available software package (PRISM, GraphPad Software, Inc., La 
Jolla, CA) or the data analysis add-in for Microsoft Excel. Either 
single factor ANOVA or Student’s t-tests were used for all analysis 
as indicated. P values of less than 0.05 were considered statistically 
significant. 
Results
Anorexigenicity. The observation that prieurianin (Figure1A) 
is a feeding deterrent in insect larvae that presumably acts by 
Figure 1: Prieurianin in mouse model of diet-induced obesity (DIO). A, Structure of prieurianin. B, C, Body weight and amount of food consumed by DIO B6 mice that 
were given either 1 or 3 mg kg-1 of prieurianin for three weeks. Prieurianin causes weight loss (B) and reduced food consumption (C) in DIO B6 mice compared 
to untreated and vehicle-treated controls. All studies consisted of ten mice per group. Statistics were conducted as an ANOVA; asterisk, P<0.05 versus untreated and 
vehicle-treated controls. Error bars indicate s.e.m.
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Figure 2: Effects of drug holiday schedule for prieurianin in DIO mice. A, B, 
Drug holiday treatment protocols for prieurianin in DIO mice. This on-off 
or cyclical treatment strategy comprised of specifi ed doses of prieurianin at 
either 3 or 5 mg kg-1 were given as indicated for a defi ned duration coupled 
with intermittent drug holiday to overcome drug-induced tolerance. C, 
D, Drug holiday treatment schedule with either 3 or 5 mg kg-1 prieurianin 
circumvented drug-induced tolerance and produced a sustained weight loss 
(C) and reduced food intake (D). All studies consisted of 10 animals per 
group, except for the 3 and 5 mg kg-1 prieurianin treated groups (n=20).
antagonizing 20-hydroxyecdysone in Drosophila cells prompted 
us to ask whether the anti-feedant effects of prieurianin can be 
exploited for the treatment of obesity. To test this hypothesis, 
we examined the effects of prieurianin on weight loss in the diet-
induced obese (DIO) C57BL/6 (B6) mice, since this model has been 
widely used to investigate the underlying mechanisms of obesity in 
human [20, 21]. DIO B6 mice were given high fat diet for 15 weeks and 
then prieurianin was administered intraperitoneally (i.p.) daily with 
either 1 or 3 mg kg-1 prieurianin for three weeks. Prieurianin caused 
a dose-dependent weight loss (Figure1B) that was accompanied by 
70-80% decrease in food consumption, which eventually returned 
to normal levels by the end of the treatment period (Figure 1C). 
Notably, a gradual regain in body weight was observed following 
the first week of treatment (Figure1B), suggesting the onset of drug-
induced tolerance. 
One of the major unresolved problems in the pharmacotherapy of 
obesity is the diminishing efficacy of drugs with chronic treatment 
[6]. To assess whether drug-induced tolerance can be circumvented 
by “drug holidays”, mice were treated with either 3 or 5 mg kg-1 
prieurianin for 5 or 3 days, respectively, followed by 5 days of drug 
withdrawal, and repeating this regimen for 4 cycles (Figure 2A and 
B). DIO B6 mice from the experiments in (Figure1) were maintained 
on the high calorie diet for four additional weeks without treatment 
and then subjected to the drug holiday treatment cycle. This 
treatment protocol, at either 3 or 5 mg kg-1 prieurianin, produced 
a greater response than daily treatment, with up to 20% weight 
loss at either dosage, and no observable weight regain at the end 
of the treatment cycle (Figure 2C). Food consumption decreased 
precipitously initially, but gradually returned to approximately 60-
70% of normal feeding and maintained at that level for the duration 
of the treatment cycle (Figure 2D). Fed glucose and insulin levels 
also showed a trend of decrease at the end of treatment period 
(Figure 3A and B). 
Anti-adipogenesis
Post-mortem analysis showed >50% decrease in subcutaneous 
and visceral fat depots in prieurianin-treated DIO B6 mice (Figure 
3C and D), compared to untreated and vehicle-treated controls. The 
ability of prieurianin to reduce fat mass led us to determine the 
effects of prieurianin on the differentiation of cultured preadipocytes 
into mature adipocytes using either the L1 preadipocytes 
[17], or the OP9 mouse stromal cells [18] that are capable of 
differentiating into adipocytes. Prieurianin inhibited the proliferation 
of L1 preadipocytes in a dose-dependent manner (Figure 4A), as 
well as their post-confluent mitosis and clonal expansion, evident 
from the reduced 3[H]thymidine uptake following differentiation 
induction (Figure 4B). Prieurianin also inhibited the differentiation 
of OP9 stromal cells into adipocytes as evident from the reduced 
Oil Red O stained lipid-accumulating  adipocytes  relative  to  the 
untreated/undifferentiated and the differentiated controls (Figure 
5A).  The positive control, TNF  [22,23], also inhibited OP9 cells 
differentiation (Figure 5A). These effects of prieurianin were 
recapitulated in the L1 preadipocytes (data not shown). The decrease 
in adipocytes was not a result of prieurianin-induced apoptosis, as 
indicated by the lack of annexin V binding to phosphatidylserine, 
in contrast to stromal cells treated with doxorubicin, a cytotoxic 
drug that causes apoptosis (Figure 4C). Similarly, apoptosis was not 
observed in prieurianin-treated L1 preadipocytes (data not shown). 
Figure 3: Effects of prieurianin on plasma glucose and insulin, and adipose 
mass in DIO mice. Plasma glucose (A) and insulin (B) levels were measured 
at the end of prieurianin treatment. Prieurianin treatment decreased plasma 
glucose (fi lled bar) and insulin (opened bar) levels in DIO mice. C, D, 
Signifi cant reduction in adipose mass was observed in post-mortem analysis 
of in subcutaneous (C) and visceral (D) compartments of prieurianin treated 
DIO B6 mice compared to untreated and vehicle (DMSO)-treated controls. 
All studies consisted of 10 animals per group, except for the 3 and 5 mg kg-1 
treated groups (n=20) in A and B. Experiments were conducted in triplicates 
for C and D selected randomly from the animals. Statistics were conducted 
as an ANOVA; asterisk, P<0.05 versus untreated and vehicle-treated controls. 
Error bars indicate s.e.m.
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To assess the effects of prieurianin in mature adipocytes, L1 
preadipocytes were differentiated into adipocytes followed by 
treatment with either TNF  or prieurianin. Consistent with previous 
report [22], TNF  induced rapid lipolysis, resulting in significant 
loss of Nile Red stained adipocytes (Figure 5B). Though less potent, 
prieurianin also caused a loss of lipid in the adipocytes, marked by 
reduced Nile Red positive cells compared to differentiated control 
and vehicle-treated cells (Figure 5B). 
Discussion
Despite a growing obese population worldwide, 
pharmacotherapy for obesity is limited as there are currently only 
two FDA-approved drugs for its treatment in U.S. Recent FDA issued 
heart risk warning in U.S. for sibutramine and its withdrawal in 
Europe, as well as new concerns for potential liver toxicity with 
orlistat, further reduced the armamentarium for the combat of 
obesity. Moreover, the use of repositioned drugs comprising 
of combinatorial mixture of anticonvulsant, antidepressant, or 
psychoactive stimulant, also poses questions of unknown longterm 
safety concerns, as these drugs all have various known risks and 
side effects [24]. These issues all point to an urgent need for the 
development of more efficacious and safe pharmacotherapeutics 
for obesity. 
Our studies here showed that prieurianin, a plant-derived 
limonoid product, which exhibits feeding deterrent activity in 
insect larvae, has biological activity in high-fat diet induced 
obese mice that results in appetite suppression, leading to 
decreased energy intake in mice and weight loss. Further, 
prieurianin also inhibits the proliferation and differentiation 
of preadipocytes, as well as causing mature adipocytes to lose 
their lipid content. These findings suggest a novel anti-obesity 
drug candidate characterized by a dual anorexigenic and anti-
adipogenic property that is distinct from currently available 
pharmaceutical therapies and pipeline products in development 
that focused on either suppressing satiety or inhibiting energy 
homeostasis [11]. The anorexigenic effect of prieurianin could not 
have been due to taste aversion because the drug was delivered 
by IP injection into the mice. Moreover, the diet choice bioassay 
in insect larvae also suggests a specific effect of prieurianin 
on feeding stimulus [14]. Although it was shown to antagonize 
20-hydroxyecdysone action in Drosophila cells [15], the precise 
mechanism of action of prieurianin, however, is unknown with 
respect to its effects on appetite suppression in mice and 
its inhibition of adipogenesis in cultured preadipocytes. It 
is noteworthy that prieurianin was recently shown to inhibit 
endocytosis and also block brassinosteroid-induced gene expression 
in germinating seedlings of Arabidopsis thaliana [25]. It is unclear 
how prieurianin-inhibited endocytosis translates into its anti-
obesity effects. Furthermore, the inhibition of hormone-induced 
transcription in germinating seedlings by prieurianin suggests that 
the drug may have similar effects on the transcriptional regulation 
of adipogenesis in preadipocytes by disrupting gene expression 
program during differentiation. Hence, identifying the molecular 
target(s) of prieurianin might yield insights into its anorexigenic 
activity in suppressing energy intake and its anti-adipogenic 
potential in the development of adipose tissue. 
Long-term efficacy and effectiveness of obesity treatments 
are known to have poor outcome [26]. The potential of drug-
induced tolerance associated with anti-obesity therapeutics is long 
recognized, but circumventing its development has not been fully 
addressed [6]. Our studies here demonstrated that drug-induced 
tolerance resulting from chronic pharmacotherapy for obesity 
could be overcome by a cyclical drug holiday treatment strategy, 
which produces a greater and more durable therapeutic response 
as evident by the sustained weight loss and reduced energy intake. 
Hence, the on-off treatment protocol may potentially restore the 
efficacy of currently available anti-obesity drugs as well as other 
experimental pharmacotherapeutics that are prone to drug-induced 
tolerance in the long-term treatment of obesity. Besides, decreasing 
the frequency of drug exposure using the drug holiday treatment 
protocol may reduce the incidence and disposition to the toxicities 
of these anti-obesity drugs. 
Figure 4: Effects of prieurianin on L1 preadipocytes and OP9 stromal 
cells. ( A), L1 preadipocytes were cultured in 12-well dishes and counted 
daily using a Coulter cell counter. Prieurianin inhibits L1 preadipocytes 
proliferation. (B), L1 preadipocytes were cultured to confl uence and then 
placed in a differentiation cocktail for 48 hours followed by 3H-thymidine uptake 
and cell lysates were subjected to scintillation counting. Prieurianin inhibits 
the postconfl uent mitosis and clonal expansion of L1 preadipocytes. (C), 
Prieurianin does not cause apoptosis in OP9 cells as measured by annexin 
V binding to cell surface phosphatidylserine, compared to the cytotoxic drug, 
doxorubicin. Studies were performed in triplicates. Asterisk, P<0.05 versus 
untreated controls. Error bars indicate s.e.m.
Figure 5: Prieurianin inhibits adipogenesis. (A), Prieurianin inhibits the 
differentiation of OP9 cells into adipocytes, stained with Oil Red O. TNFα, 
a cytokine and potent inhibitor of differentiation, is used as control. (B), 
Prieurianin causes either dedifferentiation or delipidation of differentiated 
adipocytes, stained with Nile Red, compared to untreated and vehicle-
treated adipocytes. TNF, which causes lipolysis, serves as control. All 
experiments were performed for at least three or more times and representative 
micrographs of the experiments were shown.
Citation: Kablan A, Saunders RA, Szkudlarek-Mikho M, Chin JB, Bosio RM, et al. (2010) Prieurianin Causes Weight Loss in Diet-Induced Obese Mice 
and Inhibits Adipogenesis in Cultured Preadipocytes. J Diabetes Metab 1:101. doi:10.4172/2155-6156.1000101
                                 
    
    
   
   
   
   
   
 O
MI
CS
 Pub
lishing GroupJ Diabetes Metab
ISSN:2155-6156 JDM an open access journal
Volume 1• Issue 1•1000101
Page 5 of 5
Taken together, the findings in this study showed that prieurianin 
is a novel anti-obesity therapeutic candidate that exhibits a dual 
anorexigenic and anti-adipogenic property. Therefore, investigating 
the precise molecular target of prieurianin, and characterizing 
its long-term efficacy and toxicology profile will determine its 
suitability for further development as a pharmacotherapeutic for 
obesity. 
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